News

Zacks Investment Research on MSN13h
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
CytomX Therapeutics CTMX, a clinical-stage oncology company, is expected to beat first-quarter 2025 earnings when it reports ...
Obesity drug boom has a new pecking order
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
Caribou Biosciences, Inc.: Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 ...
CURE1d
Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma
In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...
Faron Pharmaceuticals: Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025
Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies TURKU, FI / / April 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN), a clinical-stage ...
Medscape2d
Less Is More: The Case for De-escalation Strategies in Lung Cancer Management
Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...
MPR2d
FDA Denies Approval of Additional Extended Dosing Intervals for High Dose Aflibercept
After 3 initial monthly injections, current dosing intervals range from every 8 to 16 weeks in patients with wAMD and DME and every 8 to 12 weeks in patients with DR.
Clinical Pain Advisor3d
Careful Opioid Use in Acute Palliative Care Achieves Analgesia Without Dose Escalation
Among patients with advanced cancer, individualized opioid management was effective for pain control without increasing doses.